USPTO serial 79316560
Reviewed by CopyMark Law Group
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Maryann E. Licciardi
Maryann E. Licciardi Cowan, Liebowitz & Latman, P.C.114 West 47th Street, 21st FloorNew York, NY 10036-1525UNITED STATES| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Protein expression systems, namely, human proteins for life science and medical research | ACTIVE | — |
| 005 | Biological preparations for pharmaceutical and veterinary purposes, in particular biological preparations developed from biological cells for the treatment of cancer, inflammatory disease and infectious disease; biological diagnostic preparations for medical and veterinary use; cells for medical use; viral vaccines; vaccine adjuvants | ACTIVE | — |
| 040 | Custom manufacturing services of drugs; custom manufacture of pharmaceuticals; custom manufacture of proteins and vaccines and gene therapy with the aid of biological cells, including manufacture of biological active substances | ACTIVE | — |
| 042 | Research and development in the fields of bacteriology, cellular engineering, cytology, antibodies, glycomics, chemistry, microorganisms, proteins, immunology, biological therapeutics, nutraceuticals and gene expression systems; scientific research and genome synthesis in the nature of genome amplification services for others; scientific and technological research services and research services in the fields of genetics, epigenetics and expression analysis; research and development in the field of biotechnology, namely, conducting protein expression; scientific and industrial research, in particular in the field of medicine, pharmacy, molecular biology, biotechnology and genetics; research and development of drugs, diagnostic and analytical preparations, therapy procedures and expression systems; research and development services relating to vaccines; scientific research in the field of genetics and genetic engineering; research in the field of gene therapy | ACTIVE | — |
| 044 | Medical services relating to the removal, treatment and processing of human cells | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 25, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 2, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 2, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 21, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 21, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 21, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 5, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 5, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 16, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 3, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 3, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 3, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 3, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 3, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 25, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 25, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 25, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Feb 25, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 25, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 25, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jan 23, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 4, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 4, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 11, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 10, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 7, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 3, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 30, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 29, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |